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In  order  to assess the effect of increased cAMP deg- 
radation  on  the  responsiveness  on  an  endocrine cell, 
we  have  obtained  stable  transfectants of MA- 10 Leydig 
tumor cells that overexpress a mammalian CAMP- 
phosphodiesterase. Two novel cell lines, designated 
MA-lO(P+8)  and  MA-lO(P+29),  that  express  high  lev- 
els of the  transfected  enzyme  were  characterized. Al- 
though  the  basal  levels of cAMP in  the  mutant cell lines 
are comparable to those of the wild-type cells, the 
increase  in cAMP accumulation  elicited  by  human cho- 
riogonadotropin (hCG) is severely blunted. Further 
studies  with  MA-lO(P+29)  show  that  the  ability of  hCG 
to  stimulate  adenylyl  cyclase  activity is normal.  The 
failure of MA-lO(P+29)  cells  to  accumulate cAMP in 
response  to hCG can  be  correlated  with a similar  re- 
duction  in  hCG-stimulated  steroidogenesis. On the 
other  hand,  the  maximal  steroidogenic  response of  MA- 
10(P+29) cells to  dibutyryl CAMP, a cAMP  analogue 
that is fairly  resistant  to  phosphodiesterase  degrada- 
tion,  is  normal. We also  show that  the  ability of these 
cells  to  respond  to hCG with  increased cAMP  accumu- 
lation and steroid synthesis can be restored with a 
specific  phosphodiesterase  inhibitor.  These  results 
demonstrate  that  overexpression of a CAMP-phospho- 
diesterase in MA-10 cells limits the levels of cAMP 
attained  under hCG stimulation and  supresses  the  ste- 
roidogenic  response of these  cells to hCG. Since  gonad- 
otropins  increase  the CAMP-phosphodiesterase activ- 
ity in their target cells, these findings also provide 
evidence that  this  regulation plays a major  role  in the 
modulation of cell  responsiveness.  Last,  these new cell 
lines should  be  valuable in  the  study of the  actions of 
cAMP because  they express a conditional and  reversi- 
ble CAMP-resistant  phenotype. 
Desensitization of hormonal  responses  is a process  whereby 
cellular  responses  wane in  spite of the  continuous  presence of 
the hormone. Some of the  most complete studies of desensi- 
tization have  been performed using ligands  that use cAMP  as 
their second  messenger.  Although most of the  recent  studies 
on  desensitization of CAMP-mediated responses  have focused 
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on molecular events  that lead to decreases in  the  synthesis of 
cAMP (see Refs. 1 and 2 for  recent reviews), one  additional 
mechanism of desensitization  that  has received less attention 
involves stimulation of the  rate of degradation of CAMP. For 
example, follitropin and  cAMP analogues have been shown 
to  increase CAMP-phosphodiesterase activity in Sertoli cells 
(3) and  granulosa cells (4), while other  agents  that increase 
cAMP  accumulation  (such  as forskolin, prostaglandins, or (3- 
adrenergic agonists) have been shown to increase CAMP- 
phosphodiesterase activity in platelets, pineal, glioma, fat, 
and lymphoma cells (5-10). Moreover ligands that do not 
elicit increases in cAMP accumulation, such as insulin and 
muscarinic cholinergic agonists, have also been shown to 
increase  cAMP hydrolysis in  such diverse tissues  as fat cells 
(lo),  the  thyroid (ll), and  astrocytoma cells (12). 
Cyclic nucleotide phosphodiesterases  are a complex family 
of enzymes that localize to  different cellular compartments 
and whose activity can be modulated by a number of hor- 
mones, neurotransmitters,  and second messenger analogues 
(reviewed in Refs. 13 and 14). Although this complexity 
provides the  basis  for  the multiplicity of regulatory phenom- 
ena described  above, the molecular mechanisms responsible 
for the regulation of CAMP-phosphodiesterase activity and 
the consequences of such regulation are  just  beginning  to  be 
explored. With  regard  to  the molecular basis of the regulation 
of CAMP-phosphodiesterase activity,  it  seems clear that  this 
can  be accomplished  by activation of pre-existing levels of the 
enzyme(s),  and/or by increases in the  actual levels of enzyme. 
The former may be accomplished by phosphorylation of the 
enzyme(s)  as  it  appears  to occur  in  adipocytes and  platelets 
(8-10, 15), while the  latter  seems  to involve changes  in  the 
cognate mRNA as reported to occur in Sertoli and glioma 
cells (16). 
One of our  laboratories  has been  involved  in studying  the 
hormonal modulation of CAMP-phosphodiesterases and its 
involvement in the desensitization of CAMP-mediated re- 
sponses  (3,4,16,17). Although the effects of increased CAMP- 
phosphodiesterase  activity  on  cAMP metabolism have been 
studied  in some detail,  the  impact  that  this  change may have 
in cellular responses elicited by cAMP  has been  difficult to 
distinguish from changes occurring at the level of cAMP 
synthesis.  One  approach  to  this problem would be to produce 
mutant cell lines with increased CAMP-phosphodiesterase 
activity  and  to  study  the  impact of this  mutation  on  cAMP 
metabolism and actions. Although mutant cell lines with 
increased CAMP-phosphodiesterase activity have been iso- 
lated  (18), or produced by transfection with the  yeast  CAMP- 
phosphodiesterase (19, 20), the  parental  lines  (and  therefore 
the  mutants)  do  not  express CAMP-mediated  responses that 
are readily amenable  to  quantitation. 
With  this  aim  in  mind we have taken a Leydig tumor cell 
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line (designated MA-10, see Ref. 21) that exhibits an easily 
measurable CAMP-mediated response (ie. steroid biosyn- 
thesis)  and using an expression vector that encodes for the 
rat CAMP-phosphodiesterase 3 (16, 17), we have produced 
stable transfectants  that overexpress CAMP-phosphodiester- 
ase. In this paper we describe the production of these trans- 
fectants  and show that  they display a reduction in  hormone- 
stimulated cAMP levels and CAMP-mediated responses. 
EXPERIMENTAL  PROCEDURES 
Cell Culture and Transfection-The  origin and  handling of MA-10 
cells  have  been  described (21).  They were maintained  in  Waymouth 
MB752/1 modified to  contain  1.1  g/liter of NaHC03, 20 mM Hepes,' 
50 pg/ml  gentamicin, and 15% horse  serum, pH 7.4 (growth medium), 
in a  humidified atmosphere  containing 2.5%  CO,. 
Cells to be transfected were plated  in 10-cm dishes a t  a density of 
2 X lo6 cells/dish and used 1 day later. DNA transfection was 
performed  during an overnight  incubation  with Capo4  as described 
by  Chen  and  Okayama  (22) or during a 4-h incubation  with Capo4 
as described by Parker and Stark (23). In either case each dish 
received 18 yg of a rat  phosphodiesterase 3 expression  vector 
(pCMV5-ratPDE3, see Ref. 16)  and 2 pg of the selectable plasmid 
pSV,Neo. When  the  transfection  lasted only  4 h,  the cells were also 
shocked with 15% glycerol (in  Hanks'  balanced  salt  solution) for 2 
min at  room temperature at the end of the incubation with the 
plasmid/CaPO, mixture.  Following transfection,  the cells were exten- 
sively  washed with  Hanks'  balanced  salt  solution  and  reincubated  in 
growth  medium  for 1 day. The cells were trypsinized  (21),  plated  in 
several 10-cm dishes a t  a density of 0.5-1.0 X lo6 cells/dish, and 
reincubated in growth medium for 1 day. The medium was then 
replaced with growth medium supplemented with 200 pg/ml G418 
alone, or together with 5 p~ Ro 20-1724 (added from a 200-fold 
concentrated stock in dimethyl sulfoxide) as indicated in the text. 
The cells were maintained in these media for about 2 weeks with 
twice weekly media changes. Resistant colonies were isolated by 
gentle  scraping  and  suction  with a PlOOO Pipetman  and  transferred 
to  individual wells of 24-well plates.  These wells were maintained  in 
1 ml of the  appropriate medium  (see  above) and were expanded  into 
T25  flasks  as  they became confluent. As these flasks became con- 
fluent,  the cells were subcultured  into  10-cm  dishes  and  assayed for 
CAMP-phosphodiesterase activity  (see below). 
Stock  cultures of the  stable  transfectants have  always  been main- 
tained in the presence of G418 alone or G418 plus Ro 20-1724 as 
indicated below. 
Assay of CAMP-Phosphodiesterase-Experimental cultures were 
plated  (day 0) in 10-cm dishes a t  a density of 1-2 x lo6 cells/dish. 
MA-10 cells and MA-lO(P'8) cells were plated in growth medium 
(see above), while MA-l0(P+29) cells were plated  in  growth medium 
supplemented with 5 p~ Ro 20-1724. The media were replaced on 
day 2 or 3, and the experiments were performed on day 3 or 4, 
respectively. On the  day of the  experiment,  the  dishes were placed on 
ice and allowed to cool for about 30 min. They were then washed 
twice with  5-ml  portions of a  cold  buffer containing 0.25 M sucrose, 
50 mM Tris-C1, pH 7.4, scraped  into a minimal  amount of the  same 
buffer and recovered  by centrifugation. The pellets were resuspended 
in 50 mM Tris-C1, pH 8.0, containing 20 p M  leupeptin, 1 mM phenyl- 
methylsulfonyl  fluoride,  5 mM mercaptoethanol,  10 mM NaF,  and  50 
mM benzamidine.  After  a 5-min  incubation  on ice, a cell lysate was 
prepared by forcing the cell suspension 20 times  through a syringe 
fitted  with a 22-gauge needle. The lysate was  centrifuged at 800 X g 
for 10 min  and  the pellet was resuspended  in buffer, homogenized, 
and centrifuged  again as described  above. The two supernatants were 
combined and used to  assay  for  CAMP-phosphodiesterase activity. 
Assays were done basically as described by Thompson and co- 
workers (24). The reactions were performed  in a total volume of 300 
pl containing 25-100  pg  of protein  in 50 mM Tris-CI, pH 8.0, 1 mM 
mercaptoethanol, 10 mM MgCl,, a constant amount of [3H]cAMP 
(about 200,000 cpm)  and  the  indicated  concentrations f CAMP. After 
a 15-60-min incubation a t  30 "C, the tubes were transferred to a 
boiling  water bath for 45 s, and cooled in  an ice bath for  5 min. After 
' The abbreviations and trivial names used are: Hepes, N-2-hy- 
droxyethylpiperazine-N'-2-ethanesulfonic acid; EGTA,  [ethylene- 
bis(oxyethylenenitrilo)]tetraacetic acid; hCG, human choriogonado- 
tropin;  Ro 20-1724, 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidi- 
none. 
addition of  0.07 units of 5'  nucleotidase, the  tubes were incubated at 
30 "C for an additional 25 min. The reactions were terminated by 
addition of 1 ml of methanol,  and  the  [3H]cAMP  and  generated ['HI 
adenosine were separated by ion-exchange chromatography as de- 
scribed  by Thompson  and co-workers  (24). 
RNA Blot Analysis-RNA was extracted by the  method of Chirgwin 
(25)  and purified by centrifugation  on cesium  chloride (26).  Twenty 
pg of total  RNA were then glyoxylated during a 1-h  incubation (50 "C) 
in 10 pl of a solution  containing 50% (v/v)  dimethyl sulfoxide, 20% 
(v/v) glyoxal, and 20 mM sodium  phosphate, pH 6.8. The glyoxylated 
RNA  samples were resolved on a 1% agarose gel, blotted  onto nylon 
membranes  (Biotrans)  and  baked for 1 h a t  80  "C  under vacuum. The 
blots were prehybridized for  4  h a t  42 "C  and hybridized  for 16 h at 
42 "C using lo6 cpm/ml of a "'P-labeled (27) ratPDE3 cDNA in a 
solution containing 50% formamide and 5 X SCC (saline sodium 
citrate).  After  hybridization  the  blots were rinsed  with 2 X SSC, 0.1% 
sodium dodecyl sulfate  and washed twice for 20 min a t  68 "C in 0.1 
X SSC, 0.1% sodium dodecyl sulfate. The washed blots were exposed 
to  x-ray film a t  -70 "C  with  intensifying screens.  After  removal of 
this  ratPDE3  probe,  the  membranes were rehybridized with a 32P- 
labeled actin  cDNA probe. 
Zon-exchange Chromatography-Cells were cultured as described 
above, cooled on ice, washed three  times  with  5-ml  portions of ice- 
cold phosphate-buffered  saline,  and  scraped  into a minimal  amount 
of a buffer containing 20 mM Tris-C1, pH 8.0, 10 mM NaF, 1 mM 
EDTA, 0.2 mM EGTA, 50 mM benzamidine, 0.5 pg/ml leupeptin, 0.7 
pg/ml pepstatin,  and 0.12 TIU/ml  aprotinin.  Phenylmethylsulfonyl 
fluoride was then  added  to a final  concentration of 2 mM, and  the 
cells were homogenized using the tight fitting pestle of a Dounce 
homogenizer (30  strokes). Following centrifugation a t  14,000 X g  for 
30 min,  the  supernatant was adjusted  to 200 mM sodium  acetate, pH 
6.5, and  filtered  through a  0.2-pm  filter.  Aliquots of the  supernatants 
(9-33 mg of protein) were applied to a high performance liquid 
chromatography DEAE column (7.5 X 75-mm DEAE 5PW from 
Waters)  pre-equilibrated  with 200 mM sodium  acetate, pH 6.5, 5 mM 
2-mercaptoethanol, 10 mM NaF, 1 mM EDTA, 0.2 mM EGTA, 0.5 
pg/ml leupeptin, 0.7 pg/ml pepstatin,  and 0.2 mM phenylmethylsul- 
fonyl fluoride. After washing with this buffer (1 ml/min) bound 
proteins were eluted  with a linear sodium acetate  gradient (200-750 
mM) at the  same flow rate.  Each  fraction (1 ml) was adjusted to  33% 
(v/v)  ethylene glycol, and  additional  leupeptin (1 ng),  pepstatin (1.4 
ng),  phenylmethylsulfonyl fluoride  (400 nmol),  aprotinin (0.12 TIU), 
and  lima  bean  trypsin  inhibitor  (10 pg) were added  from  concentrated 
stocks.  Triplicate 15-pl aliquots  from  each  fraction were assayed  for 
phosphodiesterase  activity  (using 1 p~ cAMP  as  substrate)  during a 
15-min  incubation a t  34 "C. The activity recovered from  the  columns 
was  corrected for the  amount of protein loaded. 
Progesterone and  CAMP Leuels-Experimental cultures were 
plated  (day 0) in 6 X 35-mm wells a t  a density of  2-3 X lo5 cells/well. 
MA-10 cells and MA-10(Pf8) cells were plated in growth medium 
(see  above),  while MA-l0(P+29) cells were plated  in growth  medium 
supplemented with 5 p~ Ro 20-1724. The media were replaced on 
day 2 or 3, and the experiments were performed on day 3 or 4, 
respectively. On  the  day of the  experiment  the cells were washed  four 
times  with 2-ml portions of warm assay medium (Waymouth MB752/ 
1 modified to  contain 1.12 g/liter of NaHCOa, 20 mM Hepes, 1 mg/ 
ml bovine serum albumin, pH 7.4) and then incubated in 2 ml of 
assay medium containing  the  additions  indicated  in  the  text. Proges- 
terone  and  cAMP were measured by radioimmunoassay as previously 
described  (21, 28, 29). 
Other Methods-The procedures  used to  prepare cell membranes 
and  to  measure adenylyl cyclase activity have been described (30). 
Protein was measured by the  method of Bradford (31) using  bovine 
serum  albumin  as a standard.  The  different  parameters  that describe 
concentration-response curves were calculated with the aid of the 
computer  program  ALLFIT  (32). 
Hormones and Supplies-Purified  hCG (CR-125,11,900  units/mg) 
was obtained from the  National  Hormone  and  Pituitary Agency of 
the National Institute of Diabetes, Digestive and Kidney Diseases 
(National  Institutes of Health).  Bt2cAMP was purchased  from Sigma. 
Ro 20-1724 was obtained  from Biomol, and radioactive compounds 
were purchased from Du Pont-New England Nuclear. All tissue 
culture supplies were from  GIBCO,  and  tissue  culture plasticware was 
from Falcon or Corning. The antiserum to cAMP was generously 
provided  by Dr.  David  Garbers  (Howard  Hughes Medical Institute, 
University of Texas a t  Dallas) or Dr. Robert Ryan (Mayo Clinic). 
The pSV,Neo plasmid was  kindly  provided  by  Dr. Neal  Must0 
(Georgetown University). 
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RESULTS 
Isolation and  Initial  Characterization of Transfectants-In 
order  to  obtain  stable  transfectants  with  high  levels of CAMP- 
phosphodiesterase activity, MA-10 cells were cotransfected 
with  an  expression  vector  encoding  for  the  rat  CAMP-phos- 
phodiesterase 3 (pCMV.5-ratPDE3)  and  pSV,Neo.  One  set of 
transfectants  was  selected  in  the  presence  of  G418  only,  while 
another set was  selected  with  G418  and a CAMP-phosphodi- 
esterase  inhibitor  (Ro  20-1724).  While  the  concentration  of 
G418  used  (200  pg/ml) is lethal  to  MA-10  cells,  the  concen- 
tration of Ro 20-1724 used ( 5  PM) is not  lethal  and is similar 
t o   t h e  EC,,, required  to  enhance  the  hCG-induced  increase  in 
cAMP  accumulation  in  MA-10 cells.' We  chose t,o include a 
phosphodiesterase inhibitor as a selective agent because it 
was  possible  that  overexpression of CAMP-phosphodiesterase 
could  he  deleterious to the  growth of MA-10  cells.  Two  clones, 
isolated  from  the  two  different  transfections  and  designated 
MA-lO(P'8)  and  MA-l0(P'29),  were  chosen  for  further 
analysis. MA-lO(P'8) was selected with medium containing 
200 pg/ml G418, while MA-lO(P'29) was selected with me- 
dium containing 200 pg/ml  G418  and 5 p~ Ro 20-1724. 
Although stock cultures have always been maintained with 
G418 or G418  plus  Ro 20-1724, we  always  remove  the  G418 
from  experimental  cultures 3-4 days  prior to the  experiment. 
When using MA-l0(P+29), however, experimental cultures 
are  maintained  in  the  presence of Ro 20-1724 until   the 
beginning of the experiment. At this time the inhibitor is 
removed  by  extensively  washing  the  cells.  This  protocol  was 
adopted  because  the  presence of Ro 20-1724 until  the  begin- 
ning of the  experiment,  does  help  maintain  the  mutant  phe- 
notype in MA-lO(P'29) (see below). I t  should also he noted 
t h a t  if there were some residual inhibitor left during the 
experiment, it would  lead to an  underestimation of t h e  effect 
of increased CAMP-phosphodiesterase on the phenot-ype of 
the   mutant  cells. 
RNA  hlot  analysis of the  wild-type  and  mutant  cells  (Fig. 
1) shows  that  in  contrast  to  the  wild-type  cells,  MA-lO(P+H) 
and MA-lO(P'29) express the mRNA for the rat CAMP- 
phosphodiesterase 3 (i.e. the  mRNA  derived  from  the  trans- 
fected  cDNA,  see  above).  Densitometric  scanning of the  au-  
toradiograms (after normalization for the amount of total 
RNA present in each lane as judged by the levels of actin 
mRNA, see right p a n d  of Fig. 1) revealed t,hat the level of 
mRNA  for rat CAMP-phosphodiesterase 3 is 1.5-fold higher 
in  MA-lO(P'29)  t.han  in  MA-lO(P'8). T h e  lack of a signal  for 
t h e  wild-type  cells  in t h e  left  panel  of  Fig.  2 is explained  by 
t,he  finding  that  these  cells  do  not  express  the  homologue of 
the  rat  CAMP-phosphodiesterase 3, and   t he  levels  of mRNA 
for  the  endogenous  enzyme ( i . ~ .  equivalent  of  the  rat  CAMP- 
phosphodiesterase  2)  are  very low:' 
Additional  information  ahout  the  relative  expression f the  
endogenous  and  transfected  enzymes was obtained  by  chro- 
matography  on a DEAE-high  performance  liquid  chromatog- 
raphy  column.  The  results  presented  in  Fig.  2  show  that  while 
the  CAMP-phosphodiesterase  activity of the  wild-type  cells, 
which is the  mouse  equivalent, of the  rat  CAMP-phosphodi- 
esterase 2," elutes as a single  peak  centered  around  fraction 
17,  the  two  mut,ants also display  an  additional  peak  centered 
' Icxperiments  were done in  which  intracellular  CAMP  levels  were 
Inensured in MA-10 cells incuhated with -50 ng/ml hCG alone or 
together  with  increasing  concentrations (2.5-100 p M )  of Ro 20-172.1 
for 30 min. Half-maximal and maximal enhancement of the hCG- 
induced  cAMI'  arcumr~latinn  were  ol)tained  at 5 and 50-100 p~ Iio 
20-1 721. respect  ivrlv. 
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around fraction 2.7. This  is the expected elution position of 
the  transfected  enzyme ( L C . .  the  rat  CAMP-phosphodiesterase 
3):' These results also show that the level  of transfected 
enzyme  activity is ahout  4-fold  higher  in  MA-lO(I"29)  than 
in MA-lO(F"8). T h e  overall level ofcAMP-phosphodiesterase 
activity ( i . ~ .  endogenous + transfected) is ahout 2- and Y-fnlrt 
higher in MA-lO(P'8) and MA-lO(P'29). respectively, than 
in  the wild-t?rpe cells. 
Effpcts of hCG a n d  Ro 20-1 724 on cAMP I.mcls a n d  Adrn,vl,vl 
Cvc1a.w Activity-In order to determine the impact of i n -  
creased  CAMP-phosphodiesterase  activity  on CAMMI' accumu- 
lation, we incuhated the wild-t-ype and the two mutant cell 
lines with a saturating  concentration of hCG and rnensurerl 
' M. Conti, .I. Otleh, .J. Y. Swinncn. and \I. I'. Svot)o(h,   s~~hmittc~tl  
~~ ~~~~~~ 
for  pu1)licntion. 
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the accumulation of cAMP in  the cells and in the medium at 
different  times after addition of the hormone. These results 
are presented in Fig. 3 and show that although the basal levels 
of cAMP are comparable in  all cell lines, the ability of hCG 
to increase cAMP accumulation in MA-lO(P+8) and MA- 
10(P+29) is drastically impaired. The maximal levels of intra- 
cellular and extracellular cAMP attained by MA-lO(P’29) 
cells incubated with hCG reach only 10-20 and  5%, respec- 
tively, of those attained in the wild-type cells. The cAMP 
responses of MA-lO(P’8) cells are 1.5-2-fold higher than 
those of MA-lO(P’29) cells but are still much lower than 
those detected in the wild-type cells. These  results are con- 
sistent with the levels of CAMP-phosphodiesterase activity 
detected  in the wild-type cells and  the two mutants (cf.  Fig. 
2). In order to maximize the difference between the wild-type 
and transfected cells, however, all subsequent studies were 
done with MA-l0(P+29) only. 
If the changes summarized above are entirely due to  the 
increased levels of CAMP-phosphodiesterase, one would pre- 
dict that MA-lO(P’29) should have normal levels of adenylyl 
cyclase activity. Moreover, the cAMP responsiveness of MA- 
10(P+29) cells should be restored by addition of a CAMP- 
phosphodiesterase inhibitor. 
The first prediction is met by the results  presented  in Table 
I which show that the basal, hCG-, and NaF-stimulated 
adenylyl cyclase activities of  MA-lO(P’29) cells are very 
similar (or identical) to those of the wild-type cells. 
The second prediction was tested in the experiments  sum- 
100 I 
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FIG. 3. Time course of hCG-stimulated cAMP accumulation 
in wild-type and  mutant MA-10 cells. Cells (in 6 X 35-mm wells) 
were  washed  four times  with 2-ml portions of assay medium and  then 
incubated  in 2 ml of assay  medium containing buffer  only (basal)  or 
50 ng/ml hCG as  indicated.  Each  point  represents  the  mean k S.E. 
of four determinations  (duplicate  determinations  in two independent 
experiments). 0, MA-10, basal; 0, MA-10, hCG; 0, MA-lO(P+29), 
basal; ., MA-l0(P+29), +hCG; A, MA-lO(P+S), basal; A, MA- 
lO(P+S),  +hCG. 
TABLE I 
Adenylyl cyclase activity in   MA-10  and  MA-lO(P29) cells 
Membranes were prepared  and assayed  for  adenylyl cyclaase activ- 
ity  under  basal  conditions  or  when  stimulated  with 1 pg/ml  hCG and 
100 pM GTP,  or  with  10 mM NaF as described under  “Experimental 
Procedures.” Each value represents  the average k S.E. of 12 deter- 
minations  (four  independent  experiments  with  triplicate  determina- 
tions  in  each). 
Cell type 
cAMP formed 
Basal hCG and GTP NaF 
pmollmin X mg 
MA-10 1.8 +- 0.1 13.3 ? 0.4 144.2 ? 6.5 
MA-lO(P+29) 2.0 k 0.1 12.4 k 0.3 128.2 +- 5.9 
1 1 10 100 1000 
hCG (ngiml) 
FIG. 4. Concentration-response curves for the hCG-stimu- 
lated cAMP accumulation in wild-type and mutant MA-10 
cells. Cells (in 6 X 35-mm  wells) were washed  four times  with  2-ml 
portions of assay medium. Each well received 2 ml of assay  medium 
with or without 50 mM Ro 20-1724 as indicated. After addition of 
increasing concentrations of hCG, the wells were incubated for 30 
min,  and  intracellular  cAMP was measured  as described under  “Ex- 
perimental  Procedures.”  Each  point  represents  the  mean +- S.E. of 
four determinations (duplicate determinations in two independent 
experiments). The curves  drawn were calculated  as described under 
“Experimental  Procedures.” 
marized in Fig. 4, in which the levels of intracellular cAMP 
were measured in cells incubated for 30 min with increasing 
concentrations of hCG in the presence or absence of a maxi- 
mally effective concentration of Ro 20-1724. The results 
presented show that addition of Ro 20-1724 greatly enhances 
the levels of cAMP attained by MA-lO(P+29) cells incubated 
with  all  concentrations of hCG tested. In  the presence of Ro 
20-1724, the response of MA-l0(P+29) cells is higher than 
that detected  in MA-10 cells incubated  without the inhibitor, 
but  it is still lower than  the response of  MA-10 cells incubated 
with the inhibitor. Thus, Ro 20-1724 increases the maximal 
response of MA-10 and  MA-l0(P+29) cells from 60 to 268 and 
from 16 t o  145 pmol/106 cells, respectively. The respective 
ECSo values (reported  in  ng/ml) for the aforementioned con- 
ditions changed from 7.7 to 9.5 in MA-10, and from 10 to 6.4 
in  MA-lO(P+29) cells. 
Taken together  these  results show that  the  attenuation of 
cAMP responses detected in MA-lO(P+29) cells is entirely 
due to  the increased expression of CAMP-phosphodiesterase. 
Steroidogenic Responses-One advantage of using MA-10 
cells as a model to study the impact of increased CAMP- 
phosphodiesterase on hormonal responsiveness is their ability 
to respond to hCG and cAMP analogues with increased pro- 
gesterone synthesis (21,33,34). Inasmuch as  the steroidogenic 
effects of hCG on MA-10 cells are largely (or totally) mediated 
by cAMP (28, 35, 36), we predicted that MA-lO(P+29) would 
have a reduced steroidogenic response to hCG. 
The results  presented  in Fig. 5 show concentration-response 
curves for the steroidogenic responses of MA-10 and MA- 
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FIG. 5. Steroidogenic responses of wild-type and mutant 
MA-10 cells. Cells (in 6 X 35-mm wells) were washed four times 
with 2-ml portions of assay medium.  Each  well was then incubated 
in 2 ml of assay medium with increasing  concentrations of hCG (left 
panel)  or Bt2cAMP (right  panel) for 6 h. Extracellular  progesterone 
levels were measured as described  under  “Experimental  Procedures.” 
Each  point  represents the mean & S.E. of four determinations (du- 
plicate  determinations in two independent  experiments). The curves 
drawn were calculated as described under “Experimental  Procedures.” 
Basal  levels of progesterone were 1.9 & 0.3 and 1.5 & 0.3 ng/106 cells 
for MA-10 and MA-l0(P+29) cells,  respectively. 
10(P+29) cells to hCG and  Bt2cAMP. As can be seen  in  the 
left panel of Fig. 5, the maximal steroidogenic response to 
hCG in MA-lO(P’29) cells is only 27% of the maximal re- 
sponse  attained  in MA-10 cells (531  and  1998  ng of proges- 
terone/106 cells, respectively). The EC50 for hCG in MA- 
10(P+29) cells is  about 2-fold higher than  that  measured  in 
MA-10  cells (2.6 and 1.2 ng/ml,  respectively). In  contrast  to 
the  results  obtained  with  hCG,  the  results  presented  in  the 
right  panel of Fig. 5 show that  the steroidogenic response of 
MA-lO(P+29) cells to Bt,cAMP is only minimally affected. 
Thus,  the maximal amount of progesterone produced in  re- 
sponse  to Bt,cAMP is  the  same  in MA-10 and  MA-lO(P+29) 
cells  (1998 ng/106 cells), and  this  in  turn  is  the  same  as  the 
maximal steroidogenic response of MA-10 cells to hCG (com- 
pare left and right panels). The only  difference noted  in  the 
steroidogenic response of the wild-type and  mutant cells to 
Bt2cAMP is the EC50 which is somewhat higher in MA- 
10(P+29)  than  in MA-10  cells  (630 and 740 p ~ ,  respectively). 
The  minimal difference  between the steroidogenic responses 
of the wild-type and  mutant cells to  Bt2cAMP  presumably 
reflects the relative insensitivity of this  cAMP  analogue  to 
degradation by CAMP-phosphodiesterase  (37). 
In  the  last  series of experiments, we tested  the effects of 
Ro 20-1724 on  the steroidogenic response of MA-l0(P+29) 
cells. These  experiments  are  summarized  in Fig. 6 and show 
that Ro 20-1724 reduces the ECso for the stimulation of 
steroidogenesis by hCG (from 2.0 to  0.72 ng/ml)  in  the wild- 
type cells, but does not change the maximal steroidogenic 
response (2295 ng of progesterone/106 cells). On the other 
hand, while this  inhibitor reduces the EC50 for the  stimulation 
of  steroidogenesis  by  hCG (from 2.7 to 0.72 ng/ml)  in  MA- 
lO(P’29) cells, it  also increases the maximal steroidogenic 
response  from 756 to 2295 ng of progesterone/106 cells. The 
end  result of these  changes is that,  in  the  presence of Ro 20- 
1724, the  concentration-response curves for  the  hCG-induced 
steroidogenesis are identical in MA-10 and MA-lO(P’29) 
cells. 
These  results also show that regardless of the  sensitivity 
and  magnitude of the  cAMP  response,  the  maximal  steroido- 
genic  response to hCG is always attained when the levels of 
cAMP reach a set level. Thus, in MA-10 cells, a maximal 
steroidogenic response  is  attained at about  10 ng/ml  hCG ( c f .  
Fig. 6), a hormone  concentration  that  increases  the  intracel- 
lular levels of cAMP  to  about 40 pmol/106 cells (cf. Fig. 6). In 
MA-10 and MA-lO(P’29) cells incubated with Ro 20-1724, 
3000 , 1 
2500 1 
1 1 10 100 
hCG, nglml 
FIG. 6. Effects of Ro 20-1724 on the steroidogenic re- 
sponses of wild-type and  mutant MA-10 cells. Cells (in 6 x 35- 
mm wells) were washed four times with 2-ml portions of assay 
medium.  Each  well  received 2  ml of assay medium  with or without 50 
mM Ro 20-1724 as indicated.  After  addition of increasing  concentra- 
tions of hCG, the wells were incubated for 6 h, and extracellular 
progesterone was measured as described  under  “Experimental Pro- 
cedures.’’  Each point represents the mean ? S.E. of four determina- 
tions (duplicate determinations in two independent experiments). 
The curves drawn were calculated as described  under  “Experimental 
Procedures.” 
TABLE I1 
Effect of supplementing  the  growth  medium  with  a CAMP- 
phosphodiesterase inhibitor on CAMP levels in MA-lO(P29) cells 
MA-10 and MA-10(Pf29) cells were plated  (day 0) in 6 X 35-mm 
wells containing growth medium supplemented  with or without 5 FM 
Ro 20-1724 as indicated. The medium was replaced on day 2 and the 
cells were used on day 3.  After  extensive washing (four  times  with 2- 
ml portions of assay medium) each well received 2 ml of assay 
medium. Intracellular cAMP was measured at the end of a 30-min 
incubation with buffer or 50 ng/ml  hCG as indicated.  Each number 
represents the average & S.E. of six determinations (triplicate deter- 
minations in two indeDendent exDeriments). 
Cell type Additions to growth medium 
Intracellular  cAMP 
Basal hCG 
prnolllP cells 
MA-10 None 6.5 ? 0.1 50.8 2 5.2 
MA-lO(P+29) None 
MA-lO(P’29) RO 20-1724 4.2 & 0.4 11.2 +. 0.7 
5.8 & 0.6  24.4 f 1.9 
the maximal steroidogenic response is identical to that of 
MA-10 cells incubated  without  the  inhibitor,  but  is  attained 
a t  about 2 ng/ml hCG (c f .  Fig. 6). As shown in Fig. 6, this 
concentration of hCG  raises  the  intracellular levels of cAMP 
to  50  and 30 pmol/106 cells,  respectively, in MA-10 or MA- 
lO(P’29) cells incubated  with Ro 20-1724. 
Taken together, the results presented show that Ro 20- 
1724  completely restores  the steroidogenic  response of MA- 
lO(P’29) cells. 
Effect of Culture  Conditions  on  the cAMP Responses of the 
Mutant Cells-As summarized above, the ability of MA- 
10(P+29) cells to  respond  to hCG with  increased  cAMP  ac- 
cumulation  can be (at  least  partially)  restored by including 
Ro 20-1724 during  the  incubation. Paradoxically, the inclu- 
sion of a low concentration of the same inhibitor in the 
medium  used to  maintain  and  propagate  the cells seems  to be 
necessary to  maintain a stable  mutant  phenotype.  This  phe- 
nomenon  is  illustrated by the  data  presented  in  Table 11. In 
these  experiments  MA-lO(P+29) cells were plated  in growth 
medium supplemented  with  or  without a low concentration of 
Ro 20-1724 and cultured for 3 days. The cells were then 
washed and incubated in assay medium with or without a 
saturating  concentration of hCG  for  30 min,  and  intracellular 
14388 Genetic Manipulation of CAMP-Phosphodiesterase 
cAMP was measured. The results  presented  in  Table I1  show 
that maintaining MA-lO(P+29) cells in the absence of the 
inhibitor has little effect on the basal levels of cAMP but 
results in a %fold increase in their ability to respond to hCG 
with increased cAMP accumulation. Other experiments (not 
presented) showed that  the maximal steroidogenic response 
(to hCG) of MA-lO(P'29) cells maintained without Ro 20- 
1724  for 3 days was also higher than  the response of the cells 
continously maintained in the presence of the inhibitor. In 
additional experiments we measured CAMP-phosphodiester- 
ase activity after high performance liquid chromatography 
separation of cell-free extracts prepared from MA-lO(P'29) 
cells maintained without Ro  20-1724 for 2-3 days. Our results 
(not  presented) showed that while the levels of CAMP-phos- 
phodiesterase 2 activity remain unchanged, the levels of 
CAMP-phosphodiesterase 3 activity declined to levels com- 
parable to those detected in MA-lO(P+8), which is always 
maintained in the absence of the inhibitor. 
Although we have not yet sought an explanation for these 
findings, it is clear that MA-lO(P'29) cells must be kept in 
the presence of a phosphodiesterase inhibitor in order to 
maintain high  levels of activity of the transfected enzyme. 
DISCUSSION 
The results presented here show that transfection of  MA- 
10 Leydig tumor cells with an expression vector encoding for 
the  rat CAMP-phosphodiesterase 3 readily yields stable cell 
lines with increased levels of CAMP-phosphodiesterase activ- 
ity. Two novel cell lines, designated MA-lO(P'8) and MA- 
10(P'29), were established and characterized. These cells lines 
have increased levels of CAMP-phosphodiesterase activity, 
which is due to expression of the transfected cDNA as judged 
by RNA blot analysis, and ion-exchange chromatography 
(Figs. 1 and 2). Although the levels of CAMP-phosphodiester- 
ase  3 activity are about 4-fold higher in  MA-l0(P+29)  than in 
MA-lO(P'8), the levels of the cognate mRNA are only slightly 
higher in the former than in the  latter. Differences in the  rate 
of synthesis  and/or degradation or in protein phosphorylation 
may contribute to  this phenomenon. Moreover, it should be 
noted that  the inclusion of a low concentration of Ro  20-1724 
in  the medium  used to maintain  and propagate MA-10(P+29) 
cells seems to be (at least partially) responsible for the  in- 
creased levels of CAMP-phosphodiesterase activity and re- 
duced cAMP responses detected in this cell line once the 
inhibitor is removed (see "Results" and Table 11). Future 
experiments will further examine the molecular basis of the 
differential expression of CAMP-phosphodiesterase activity 
between these two  cell lines. 
Although the basal levels of cAMP are comparable in the 
wild-type and  mutant cells (Fig. 3, Table 11), the elevation of 
cAMP levels that occurs following hCG stimulation  are se- 
verely limited, and  this  limitation varies in parallel with the 
levels of CAMP-phosphodiesterase activity. Thus,  the cAMP 
responses to hCG stimulation are more blunted in MA- 
lO(P'29) than in MA-lO(P'8) (Fig. 3), and the response of 
MA-lO(P'29) can be manipulated with a phosphodiesterase 
inhibitor in a predictable fashion (Fig. 4). These  results  indi- 
cate that while the basal levels of cAMP do not reflect 
phosphodiesterase activity, the hormone-stimulated levels of 
cAMP attained by MA-10 cells are, to a large extent,  dictated 
by the activity of this enzyme. This is true even in  the wild- 
type cells  where the inclusion of phosphodiesterase inhibitors 
such as Ro 20-1724 (Fig. 4) or 3-isobutyl-1-methylxanthine 
(33, 38) have little or no effect on the basal levels of CAMP, 
but greatly enhance the hCG-induced CAMP-accumulation. 
A similar phenomenon was also noted in Chinese hamster 
ovary cells transfected with the yeast CAMP-phosphodiester- 
ase. These cells have normal basal levels of cAMP but show 
a greatly reduced response to prostaglandin El and cholera 
toxin (19). 
One notable advantage of using MA-10 cells for these 
experiments is that they respond to hCG and cAMP analogues 
with a robust increase in steroid synthesis (21, 33,34). More- 
over, as discussed elsewhere (28, 35, 36) the steroidogenic 
response to hCG is largely (or totally) mediated by CAMP. 
Thus,  the reduced ability of MA-lO(P'29) to respond to hCG 
with increased cAMP accumulation can be easily correlated 
with a similar reduction in hCG-stimulated steroidogenesis 
(Figs. 5 and 6). In contrast to the large reduction in the 
maximal steroidogenic response to hCG, the maximal ste- 
roidogenic response of MA-lO(P'29) cells to Bt,cAMP is 
normal (Fig. 5), presumably because this cAMP analogue is a 
poor substrate for the CAMP-phosphodiesterase (see "Re- 
sults''). An additional illustration of the importance of in- 
creased CAMP-phosphodiesterase activity in limiting CAMP- 
mediated responses in MA-lO(P'29) cells is provided by the 
finding that addition of Ro 20-1724 during the incubation 
with hCG restores the cAMP and steroidogenic responses 
(Figs. 4  and 6) 
The finding that  the reduced responsiveness of MA- 
10(P+29) cells to hCG can be  overcome with cAMP analogues 
that are relatively insensitive to phosphodiesterase degrada- 
tion, or by addition of a phosphodiesterase inhibitor,  estab- 
lishes these new cell lines as rather flexible experimental 
paradigms. Together with another  stable  transfectant of MA- 
10 cells (designated MA-lO(K3)) that have reduced levels of 
CAMP-dependent protein kinase activity (36), MA-lO(P'29) 
cells provide us with valuable tools to examine the metabolism 
of cAMP and  to assess the role of cAMP as  a mediator of 
steroid synthesis or other  actions of hCG (39). 
It has been proposed that  the refractoriness of Sertoli cells 
that occurs following treatment with follitropin is due, at least 
in part, to a 10-fold increase in the activity of a CAMP- 
phosphodiesterase similar to  the  rat CAMP-phosphodiesterase 
3 (3, 40). Since desensitization of adenylyl cyclase occurred 
within the same time frame, conclusive proof of the role  of 
phosphodiesterase activation in the refractoriness of the cells 
could not be obtained. Since the  data presented here show 
that a 5-7-fold increase in CAMP-phosphodiesterase activity 
causes an 80-95% reduction in cAMP accumulation, it can be 
inferred that  the 10-fold increase in phosphodiesterase activ- 
ity previously shown to occur in Sertoli cells must have a 
profound effect on cAMP accumulation. Thus, our data  sup- 
port the notion that activation of a CAMP-phosphodiesterase 
plays a pivotal role in the follitropin-induced desensitization 
of Sertoli cell responsiveness. 
Last, since in several cell types hormone-mediated increases 
in cAMP accumulation lead to  an increase in  the levels of a 
CAMP-phosphodiesterase similar to  the transfected rat phos- 
phodiesterase 3 (3-7, 16), our results provide evidence that 
this regulation limits cell responsiveness. 
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